All Oncology News

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

Will the FDA approve T-DXd for HER2-positve early breast cancer with residual disease after HER2-targeted neoadjuvant therapy?

Continuing treatment with zenocutuzumab beyond disease progression was effective and safe in patients with advanced NRG1+ NSCLC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

Mezigdomide plus carfilzomib and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma.

Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

The FDA has received a resubmitted sBLA for nogapendekin alfa inbakicept in BCG-unresponsive NMIBC with papillary-only tumors.

Peter WT Pisters, MD, received the Charles M. Balch, MD, Distinguished Service Award at the 2026 Society of Surgical Oncology Annual Meeting 

Jasleen Pannu, MBBS, explains how interventional pulmonologists guide timely molecular testing and treatment through lung cancer diagnosis, staging, and tissue acquisition.

Findings presented at the Miami Breast Cancer Conference support using T-DXd across a wide range of real-world patients in community cancer settings.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

Priyanka Sharma, MD, discusses potential neoadjuvant de-escalation strategies in HER2-positive breast cancer.

The FDA has cleared Pylarify TruVu injection, a new formulation of its F 18 PSMA imaging agent for prostate cancer.

W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

Dato-DXd plus durvalumab showed promising efficacy in locally advanced or metastatic triple-negative breast cancer.

Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Ultra-hypofractionted radiotherapy yielded responses in locally advanced breast cancer.

T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

A ctDNA blood test predicted metastatic risk, but not local recurrence, after bladder-sparing cancer treatment.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer during CRC awareness month.

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

Data from KEYNOTE-B96 supported the first FDA approval of an immunotherapy regimen in PD-L1–positive platinum-resistant, recurrent ovarian cancer.